Please use this identifier to cite or link to this item: http://doi.org/10.25358/openscience-6098
Full metadata record
DC FieldValueLanguage
dc.contributor.authorWelker, Armin-
dc.contributor.authorKersten, Christian-
dc.contributor.authorMüller, Christin-
dc.contributor.authorMadhugiri, Ramakanth-
dc.contributor.authorZimmer, Collin-
dc.contributor.authorMüller, Patrick-
dc.contributor.authorZimmermann, Robert-
dc.contributor.authorHammerschmidt, Stefan-
dc.contributor.authorMaus, Hannah-
dc.contributor.authorZiebuhr, John-
dc.contributor.authorSotriffer, Christoph-
dc.contributor.authorSchirmeister, Tanja-
dc.date.accessioned2021-06-28T10:43:44Z-
dc.date.available2021-06-28T10:43:44Z-
dc.date.issued2021-
dc.identifier.urihttps://openscience.ub.uni-mainz.de/handle/20.500.12030/6107-
dc.description.abstractInhibition of coronavirus (CoV)-encoded papain-like cysteine proteases (PLpro) represents an attractive strategy to treat infections by these important human pathogens. Herein we report on structure-activity relationships (SAR) of the noncovalent active-site directed inhibitor (R)-5-amino-2-methyl-N-(1-(naphthalen-1-yl)ethyl) benzamide (2 b), which is known to bind into the S3 and S4 pockets of the SARS-CoV PLpro. Moreover, we report the discovery of isoindolines as a new class of potent PLpro inhibitors. The studies also provide a deeper understanding of the binding modes of this inhibitor class. Importantly, the inhibitors were also confirmed to inhibit SARS-CoV-2 replication in cell culture suggesting that, due to the high structural similarities of the target proteases, inhibitors identified against SARS-CoV PLpro are valuable starting points for the development of new pan-coronaviral inhibitors.en_GB
dc.language.isoengde
dc.rightsCC BY*
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/*
dc.subject.ddc570 Biowissenschaftende_DE
dc.subject.ddc570 Life sciencesen_GB
dc.subject.ddc610 Medizinde_DE
dc.subject.ddc610 Medical sciencesen_GB
dc.titleStructure-activity relationships of benzamides and isoindolines designed as SARS-CoV protease inhibitors effective against SARS-CoV-2en_GB
dc.typeZeitschriftenaufsatzde
dc.identifier.doihttp://doi.org/10.25358/openscience-6098-
jgu.type.dinitypearticleen_GB
jgu.type.versionPublished versionde
jgu.type.resourceTextde
jgu.organisation.departmentFB 09 Chemie, Pharmazie u. Geowissensch.de
jgu.organisation.number7950-
jgu.organisation.nameJohannes Gutenberg-Universität Mainz-
jgu.rights.accessrightsopenAccess-
jgu.journal.titleChemMedChemde
jgu.journal.volume16de
jgu.journal.issue2de
jgu.pages.start340de
jgu.pages.end354de
jgu.publisher.year2021-
jgu.publisher.nameWiley-VCHde
jgu.publisher.placeWeinheim u.a.de
jgu.publisher.urihttps://doi.org/10.1002/cmdc.202000548de
jgu.publisher.issn1860-7187de
jgu.organisation.placeMainz-
jgu.subject.ddccode570de
jgu.subject.ddccode610de
jgu.publisher.doi10.1002/cmdc.202000548
jgu.organisation.rorhttps://ror.org/023b0x485
Appears in collections:JGU-Publikationen

Files in This Item:
  File Description SizeFormat
Thumbnail
welker_armin-structure-acti-20210621155711267.pdf2.04 MBAdobe PDFView/Open